US Flag logoAn official website of the United States government
MP2PRT: Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2
GDC
Data Resource:  GDC
Point of Contact:  
Elizabeth Jones Perlman, MD,  
Project

About This Dataset
The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled "Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2", performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples.
Core Data Elements
Number of Cases
1,559
Case Sex
Female (554); Male (700); Not Reported (305)
Case Age At Diagnosis
0 to 4 years (1,146); 5 to 9 years (373); 10 to 14 years (27); 15 to 19 years (11); 20 to 24 years (2)
Case Race
American Indian or Alaska Native (5); Asian (43); Black or African American (74); Native Hawaiian or Other Pacific Islander (1); White (982); Not Reported (306); Unknown (148)
Case Ethnicity
Hispanic or Latino (256); Not Hispanic or Latino (958); Not Reported (305); Unknown (40)
Case Disease Diagnosis
Acute leukemia, NOS (8); Acute lymphoblastic leukemia, NOS (115); Blastic plasmacytoid dendritic cell neoplasm (1); Chronic lymphocytic leukemia (1); Common precursor B ALL (998); Leukemia, NOS (51); Lymphoid leukemia, NOS (1); Neoplasm, uncertain whether benign or malignant (1); Nephroblastoma, NOS (52); Osteosarcoma, NOS (1); Precursor B-cell lymphoblastic leukemia (11); Precursor cell lymphoblastic leukemia, NOS (5); Precursor cell lymphoblastic leukemia, not phenotyped (7); Subacute lymphoid leukemia (1); Not Reported (305); Unknown (1)
Case Tumor Site
Blood (62); Bone Marrow (1,140); Kidney (52); Not Reported (305)
Number of Samples
13,489
Sample Assay Method
miRNA Sequencing (195); RNA Sequencing (585); Whole Genome Sequencing (12,709)
Additional Data Elements
CLINICAL TRIAL IDENTIFIER
DBGAP STUDY IDENTIFIER
DATA REPOSITORY
Grant Information
HHSN261201500003I
Contract
Charts
Male (700); Female (554); Not Reported (305)
700Male